Literature DB >> 22769053

Metastin levels in pregnancies complicated by pre-eclampsia and their relation with disease severity.

Ertan Adali1, Zehra Kurdoglu, Mertihan Kurdoglu, Mansur Kamaci, Ali Kolusari, Recep Yildizhan.   

Abstract

AIMS: To evaluate the role of metastin levels in the pathophysiology of pre-eclampsia and to determine whether there is a relationship between the severity of the disease and Doppler velocimetry measurements.
METHODS: This cross-sectional study included 89 pregnant women (50 healthy normotensive pregnant women, 15 patients with mild pre-eclampsia, and 24 patients with severe pre-eclampsia) at the third trimester of pregnancy. The maternal levels of plasma metastin were determined by enzyme-linked immunosorbent assay. The umbilical artery and uterine artery blood flow velocities were measured by transabdominal color and pulsed Doppler ultrasound.
RESULTS: Plasma metastin levels were lower in patients with pre-eclampsia than those in the normotensive pregnant women. Four patients with mild pre-eclampsia and seven patients with severe pre-eclampsia had abnormal Doppler velocimetry findings. Metastin levels of pre-eclamptic patients with abnormal Doppler velocimetry findings were significantly lower than those in patients with normal Doppler velocimetry findings. Plasma metastin levels negatively correlated with proteinuria in 24 hours and with mean arterial pressure in the cases of pre-eclampsia.
CONCLUSIONS: The findings suggest that decreased maternal concentrations of plasma metastin may be involved in the pathogenesis of pre-eclampsia. Plasma metastin levels may be useful in the assessment of the severity of pre-eclampsia. However, further trials are needed to clarify the role of metastin in pre-eclampsia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22769053     DOI: 10.3109/14767058.2012.708369

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  6 in total

Review 1.  The Role of Kisspeptin in the Pathogenesis of Pregnancy Complications: A Narrative Review.

Authors:  Magdalena Szydełko-Gorzkowicz; Elżbieta Poniedziałek-Czajkowska; Radzisław Mierzyński; Maciej Sotowski; Bożena Leszczyńska-Gorzelak
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

Review 2.  From inhibition of trophoblast cell invasion to proapoptosis: what are the potential roles of kisspeptins in preeclampsia?

Authors:  Viviane C L Gomes; Jenny L Sones
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-05-19       Impact factor: 3.210

Review 3.  Kisspeptin in the Prediction of Pregnancy Complications.

Authors:  Jovanna Tsoutsouki; Bijal Patel; Alexander N Comninos; Waljit S Dhillo; Ali Abbara
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-19       Impact factor: 6.055

4.  Kisspeptin treatment improves fetal-placental development and blocks placental oxidative damage caused by maternal hypothyroidism in an experimental rat model.

Authors:  Bianca Reis Santos; Jeane Martinha Dos Anjos Cordeiro; Luciano Cardoso Santos; Erikles Macedo Barbosa; Letícia Dias Mendonça; Emilly Oliveira Santos; Isabella Oliveira de Macedo; Mário Sergio Lima de Lavor; Raphael Escorsim Szawka; Rogeria Serakides; Juneo Freitas Silva
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

5.  Potential roles for the kisspeptin/kisspeptin receptor system in implantation and placentation.

Authors:  Kai-Lun Hu; Hsun-Ming Chang; Hong-Cui Zhao; Yang Yu; Rong Li; Jie Qiao
Journal:  Hum Reprod Update       Date:  2019-05-01       Impact factor: 15.610

6.  Changes in Circulating Kisspeptin Levels During Each Trimester in Women With Antenatal Complications.

Authors:  Ali Abbara; Maya Al-Memar; Maria Phylactou; Elisabeth Daniels; Bijal Patel; Pei C Eng; Rans Nadir; Chioma Izzi-Engbeaya; Sophie A Clarke; Edouard G Mills; Tia Hunjan; Ewa Pacuszka; Lisa Yang; Paul Bech; Tricia Tan; Alexander N Comninos; Tom W Kelsey; Christopher Kyriacou; Hanine Fourie; Tom Bourne; Waljit S Dhillo
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.